Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies

被引:322
作者
Lakatos, Peter Laszlo [1 ]
Lakatos, Laszlo [2 ]
机构
[1] Semmelweis Univ, Dept Med 1, Koranyi Str 2-A, H-4083 Budapest, Hungary
[2] Csolnoky F Cty Hosp, Dept Med 1, H-8201 Veszprem, Hungary
关键词
ulcerative colitis; colorectal cancer; risk factors; surveillance; chemprevention;
D O I
10.3748/wjg.14.3937
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The risk of colorectal cancer for any patient with ulcerative colitis is known to be elevated, and is estimated to be 2% after 10 years, 8% after 20 years and 18% after 30 years of disease. Risk factors for cancer include extent and duration of ulcerative colitis, primary sclerosing cholangitis, a family history of sporadic colorectal cancer, severity of histologic bowel inflammation, and in some studies, young age at onset of colitis. In this review, the authors discuss recent epidemiological trends and causes for the observed changes. Population-based studies published within the past 5 years suggest that this risk has decreased over time, despite the low frequency of colectomies. The crude annual incidence rate of colorectal cancer in ulcerative colitis ranges from approximately 0.06% to 0.16% with a relative risk of 1.0-2.75. The exact mechanism for this change is unknown; it may partly be explained by the more widespread use of maintenance therapy and surveillance colonoscopy. (C) 2008 The WJG Press. All rights reserved.
引用
收藏
页码:3937 / 3947
页数:11
相关论文
共 101 条
[81]   Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis [J].
Rutter, MD ;
Saunders, BP ;
Schofield, G ;
Forbes, A ;
Price, AB ;
Talbot, IC .
GUT, 2004, 53 (02) :256-260
[82]   Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis [J].
Rutter, MD ;
Saunders, BP ;
Wilkinson, KH ;
Rumbles, S ;
Schofield, G ;
Kamm, MA ;
Williams, CB ;
Price, AB ;
Talbot, IC ;
Forbes, A .
GASTROENTEROLOGY, 2006, 130 (04) :1030-1038
[83]   Most dysplasia in ulcerative colitis is visible at colonoscopy [J].
Rutter, MD ;
Saunders, BP ;
Wilkinson, KH ;
Kamm, MA ;
Williams, CB ;
Forbes, A .
GASTROINTESTINAL ENDOSCOPY, 2004, 60 (03) :334-339
[84]   Aminosalicylates and colorectal cancer in IBD: A not-so bitter pill to swallow [J].
Ryan, BM ;
Russel, MGVM ;
Langholz, E ;
Stockbrugger, RW .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (08) :1682-1687
[85]  
Sato F, 2002, CANCER RES, V62, P1148
[86]   Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability [J].
Schulmann, K ;
Mori, Y ;
Croog, V ;
Yin, J ;
Olaru, A ;
Sterian, A ;
Sato, F ;
Wang, SN ;
Xu, Y ;
Deacu, E ;
Berki, AT ;
Hamilton, JP ;
Kan, T ;
Abraham, JM ;
Schmiegel, W ;
Harpaz, N ;
Meltzer, SJ .
GASTROENTEROLOGY, 2005, 129 (01) :74-85
[88]  
Shetty K, 1999, AM J GASTROENTEROL, V94, P1643
[89]   Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease [J].
Stange, E. F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 :64-67
[90]   Specific clinical and biological features characterize inflammatory bowel disease-associated colorectal cancers showing Microsatellite instability [J].
Svrcek, Magali ;
El-Bchiri, Jamila ;
Chalastanis, Alexandra ;
Capel, Emilie ;
Dumont, Sylvie ;
Buhard, Olivier ;
Oliveira, Carla ;
Seruca, Raquel ;
Bossard, Celine ;
Mosnier, Jean-Francois ;
Berger, Francoise ;
Leteurtre, Emmanuelle ;
Lavergne-Slove, Anne ;
Chenard, Marie-Pierre ;
Hamelin, Richard ;
Cosnes, Jacques ;
Beaugerie, Laurent ;
Tiret, Emmanuel ;
Duval, Alex ;
Flejou, Jean-Francois .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4231-4238